Budralazine

CAS : 36798-79-5

Ref. 3D-LBA79879

Informations sur le produit

• Nom: Budralazine
• Synonymes: 1(2H)-Phthalazinone, (1,3-dimethyl-2-butenylidene)hydrazone, 1-(2-(1,3-Dimethyl-2-Butenylidene)Hydrazino)Phthalazine, 1-[(2E)-2-(1,3-dimethylbut-2-en-1-ylidene)hydrazino]phthalazine, 1-[2-(1,3-Dimethyl-2-buten-1-ylidene)hydrazino]phthalazine, 1-[2-(4-Methylpent-3-En-2-Ylidene)Hydrazinyl]Phthalazine, 3-Penten-2-one, 4-methyl-, 2-(1-phthalazinyl)hydrazone, Buterazine, Dj 1461

Description

Budralazine is an inhibitor of the enzyme phosphofructokinase, which is responsible for the conversion of fructose-6-phosphate to fructose-1,6-bisphosphate. It also inhibits mitochondrial ATPase and adenylate kinase, thereby inhibiting oxidative metabolism. This inhibition leads to a decrease in the levels of nucleotides, such as adenosine triphosphate (ATP), and an increase in the levels of 5-hydroxytryptamine (5-HT). Budralazine has been shown to produce genotoxic effects in cardiac tissue and anesthetized rats. This drug also induces symptoms that are similar to those seen in inflammatory bowel disease and is toxic at high doses. Pharmacokinetic studies have shown that budralazine is eliminated rapidly from plasma with a half life of approximately 2 hours. The drug has been shown to have cardiac effects on congestive heart failure patients and can cause bowel disease when administered orally.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 240.3 g/mol
• Formule: C₁₄H₁₆N₄
• Degré de pureté: Min. 95%